SCHOTT Pharma AG & Co. KGaA (1SXP XETRA) stock market data APIs
€23.8995
-0.07(-0.3%)
as of April 25, 2025
SCHOTT Pharma AG & Co. KGaA Financial Data Overview
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container. It also provides products comprising cartriQ, a pharmaceutical glass cartridge for peptide and protein-based injectables; cartriQ Large Volume, a pharmaceutical glass cartridge for large-volume injectables; Cartridges Double Chamber, a pharmaceutical glass cartridge for lyophilized drugs; Cartridges Break Resistant, a pharmaceutical glass cartridge; and TopLine and StandardLine cartridges. In addition, the company offers adaptiQ, a pharmaceutical glass vial for injectables; EVERIC pure, a pharmaceutical glass vial for unmatched drug stability; EVERIC care, a pharmaceutical glass vial for a pH range; EVERIC strong & smooth, a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for lyophilized drugs; and TopLine and StandardLine vials. Further, it provides ampoule products comprise Ampoules easyOPC, a pharmaceutical glass ampoule for ampoule opening; Ampoules Anti-Counterfeiting, a pharmaceutical glass ampoule for protection against drug counterfeiting; and StandardLine ampoules. The company was founded in 1884 and is headquartered in Mainz, German
Prev. Close
23.8995
Open
23.8302
High
24.0945
Low
23.508
52 wk Range
18.5-40.1202
Market Cap
3 570 M
P/E Ratio
26.6292
Shares Outstanding
151 M
Revenue
955 M
EPS
0.19
Dividends (Yield)
0.0068
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SCHOTT Pharma AG & Co. KGaA data using free add-ons & libraries
Get SCHOTT Pharma AG & Co. KGaA Fundamental Data
SCHOTT Pharma AG & Co. KGaA Fundamental data includes:
- Net Revenue: 955 M
- EBITDA: 245 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-13
- EPS/Forecast: 0.1876
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SCHOTT Pharma AG & Co. KGaA News
New
SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
SCHOTT Pharma KGaA (ETR:1SXP) has had a rough three months with its share price down 5.4%. However, stock prices are usually driven by a company’s financial performance over the long term, which in ...
Analyst Estimates: Here's What Brokers Think Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) After Its First-Quarter Report
Last week saw the newest quarterly earnings release from SCHOTT Pharma AG & Co. KGaA (ETR:1SXP), an important milestone in the company's journey to build a stronger business. SCHOTT Pharma KGaA report...
SCHOTT Pharma KGaA First Quarter 2025 Earnings: EPS Beats Expectations
SCHOTT Pharma KGaA (ETR:1SXP) First Quarter 2025 Results Key Financial Results Revenue: €229.8m (down 1.0% from 1Q 2024). Net income: €28.9m (down 35% from 1Q 2024). Profit margin: 13% (down fro...
SCHOTT Pharma KGaA Full Year 2024 Earnings: EPS Beats Expectations
SCHOTT Pharma KGaA (ETR:1SXP) Full Year 2024 Results Key Financial Results Revenue: €957.1m (up 6.5% from FY 2023). Net income: €149.7m (down 1.4% from FY 2023). Profit margin: 16% (down from 17...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
